ERBB2 and breast cancer: Patients with MBC exhibited a lower OS rate compared with FBC across all tumor subtypes, TNBC (5-yr OS: 61% vs. 74%; 10-yr OS: 57% vs. 64%; p < 0.001), HER2+BC (5-yr OS: 71% vs. 84%; 10-yr OS: 54% vs. 72%; p < 0.001), and HR+/HER2- BC (5-yr OS: 75% vs. 86%; 10-yr OS: 55% vs. 72%; p < 0.001).